Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | PDE2A | O00408 | 4/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.35 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.35 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.35 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.35 |
| ▸ | NNMT | P40261 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | PDE6D | O43924 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL911440 | 0.77 | HPGD (0.40) | CYP1A2KMT2AHPGDTSHRSMN1; SMN2 | |
| SCHEMBL2969903 | 0.77 | CYP1A2 (0.41) | CYP1A2KMT2APOLBTDP1PDE10A | |
| SCHEMBL13865700 | 0.76 | NNMT (0.48) | CYP1A2KMT2AHPGDTSHRSMN1; SMN2 | |
| SCHEMBL27582225 | 0.76 | POLB (0.50) | CYP1A2KMT2AHPGDTSHRSMN1; SMN2 | |
| SCHEMBL20394372 | 0.76 | POLB (0.41) | CYP1A2KMT2AHPGDSMN1; SMN2HSD17B10 | |
| SCHEMBL31414709 | 0.76 | POLB (0.41) | CYP1A2KMT2AHPGDSMN1; SMN2HSD17B10 | |
| SCHEMBL2317842 | 0.74 | SIRT2 (0.43) | CYP1A2KMT2AHPGDTSHRSMN1; SMN2 | |
| SCHEMBL12677821 | 0.74 | CYP1A2 (0.39) | CYP1A2KMT2APOLBTDP1PDE10A | |
| SCHEMBL22564747 | 0.74 | HPGD (0.38) | CYP1A2KMT2AHPGDTSHRSMN1; SMN2 | |
| SCHEMBL15512652 | 0.74 | HTT (0.37) | CYP1A2KMT2AHPGDTSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078130-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | SIRONAX LTD (KY) | 2026-03-19 | — | — | US | disclosed |
| EP-4642782-A2 | ALPHA-V-BETA-8 INTEGRIN INHIBITORS AND USES THEREOF | Pliant Therapeutics, Inc. (US) | 2025-11-05 | — | — | EP | disclosed |
| EP-4590674-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd (KY) | 2025-07-30 | — | — | EP | disclosed |
| US-20240245682-A1 | ALPHA-V-BETA-8 INTEGRIN INHIBITORS AND USES THEREOF | PLIANT THERAPEUTICS, INC. | 2024-07-25 | — | — | US | disclosed |
| WO-2024145245-A2 | ALPHA-V-BETA-8 INTEGRIN INHIBITORS AND USES THEREOF | PLIANT THERAPEUTICS, INC. (US) | 2024-07-04 | — | — | WO | disclosed |
| WO-2024095005-A1 | DIARYL DIAZOLE AND DIARYL TRIAZOLE DERIVATIVES FOR USE IN TREATING A DISEASE ASSOCIATED WITH KCNK13 ACTIVITY | Cerevance, Inc. (US) | 2024-05-10 | — | — | WO | disclosed |
| WO-2024061340-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2024-03-28 | — | — | WO | disclosed |
| CN-106866737-B | Phosphonic acid derivatives and their use | 南京圣和药物研发有限公司 | 2020-11-20 | — | — | CN | disclosed |
| WO-2013078254-A1 | BICYCLIC HETEROARYL DERIVATIVES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2013-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078130-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | NAMPT, NNMT, SARM1 | CYP1A2 1868/4885KMT2A 2737/4885HPGD 520/4885 |
| US-20240245682-A1 | ALPHA-V-BETA-8 INTEGRIN INHIBITORS AND USES THEREOF | ITGB8, ITGAV, ITGA8 | CYP1A2 3982/4885KMT2A 2783/4885HPGD 3154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.